Literature DB >> 15690202

Significance of vascular endothelial growth factor and epidermal growth factor in development of papillary thyroid cancer.

Aleksander Konturek1, Marcin Barczyński, Stanisław Cichoń, Anna Pituch-Noworolska, Jacek Jonkisz, Wojciech Cichoń.   

Abstract

BACKGROUND AND AIMS: Vascular endothelial growth factor (VEGF) induces proliferation of endothelial cells, stimulates angiogenesis and increases vascular permeability. Epidermal growth factor (EGF) induces proliferation of epidermal cells and stimulates epidermal migration. Increased VEGF and EGF expression have been associated with poor clinical outcome in many malignancies. Several recent reports have shown overexpression of VEGF and EGF in papillary thyroid cancer (PTC). The study aimed to determine the intensity of expression of VEGF and EGF in patients with PTC and to find any correlation between the intensity of the expression and staging of the disease at the moment of surgery PATIENTS AND METHODS: The study comprised a group of 48 consecutive patients with PTC who underwent radical surgery. The group consisted of 11, 25, eight and four patients at pT1N0M0, pT2N0M0, pT3N1M0 and pT4N1M0 stages, respectively. The control group was composed of 20 healthy bone marrow transplant donors, age-, gender- and BMI-matched with PTC patients. The immuno-chemiluminescence enzyme linked immunoassay (ELISA) method was used to determine the expression and level of VEGF and EGF in serum samples. Patients' characteristics, serum levels of VEGF and EGF, final histology and pTNM were analysed.
RESULTS: The mean serum level of VEGF and EGF was remarkably higher in PTC patients than in controls. A negative correlation between staging in pTNM classification and the mean serum VEGF level (r=-0.5168; P<0.05) as well as a positive correlation between staging in pTNM classification and the mean serum EGF level (r=0.6104; P<0.05) in PTC patients was observed.
CONCLUSIONS: Both VEGF and EGF play an important role in PTC growth. However, the intensity of their expression is variable, depending on the stage of the disease. The highest intensity of VEGF expression is characteristic for low-stage T1N0M0 disease, whereas the highest intensity of EGF expression is more often found at locally advanced pT3 and pT4N1M0 stages of the disease. Further long-term follow-up studies are required to demonstrate the prognostic value of VEGF and EGF in PTC, particularly in identification of patients with expected poor prognosis or shorter recurrence-free survival.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15690202     DOI: 10.1007/s00423-004-0529-0

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  23 in total

Review 1.  Mechanisms of angiogenesis and arteriogenesis.

Authors:  P Carmeliet
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

Review 2.  Vasculogenesis, angiogenesis, and growth factors: ephrins enter the fray at the border.

Authors:  G D Yancopoulos; M Klagsbrun; J Folkman
Journal:  Cell       Date:  1998-05-29       Impact factor: 41.582

Review 3.  Mechanisms of angiogenesis.

Authors:  W Risau
Journal:  Nature       Date:  1997-04-17       Impact factor: 49.962

4.  Thyrotropin modulates EGF receptor function in porcine thyroid follicle cells.

Authors:  K Westermark; F A Karlsson; B Westermark
Journal:  Mol Cell Endocrinol       Date:  1985-04       Impact factor: 4.102

Review 5.  Growth regulation of thyroid and thyroid tumors in humans.

Authors:  P E Goretzki; D Simon; C Dotzenrath; K M Schulte; H D Röher
Journal:  World J Surg       Date:  2000-08       Impact factor: 3.352

6.  Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells.

Authors:  F Okada; J W Rak; B S Croix; B Lieubeau; M Kaya; L Roncari; S Shirasawa; T Sasazuki; R S Kerbel
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

7.  Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancer.

Authors:  Shih Y Lin; Ya Y Wang; Wayne H-H Sheu
Journal:  Clin Endocrinol (Oxf)       Date:  2003-04       Impact factor: 3.478

Review 8.  Chemokine biology in cancer.

Authors:  Fran Balkwill
Journal:  Semin Immunol       Date:  2003-02       Impact factor: 11.130

9.  Prognostic value of vascular endothelial growth factor expression in gastric carcinoma.

Authors:  K Maeda; Y S Chung; Y Ogawa; S Takatsuka; S M Kang; M Ogawa; T Sawada; M Sowa
Journal:  Cancer       Date:  1996-03-01       Impact factor: 6.860

10.  Prognostic impact of EGF-receptor in papillary thyroid carcinoma.

Authors:  L A Akslen; A O Myking; H Salvesen; J E Varhaug
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

View more
  7 in total

1.  Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines.

Authors:  S Hoffmann; A Burchert; A Wunderlich; Y Wang; S Lingelbach; L C Hofbauer; M Rothmund; A Zielke
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

2.  High expression of GPER1, EGFR and CXCR1 is associated with lymph node metastasis in papillary thyroid carcinoma.

Authors:  Cui Tang; Lei Yang; Ni Wang; Li Li; Man Xu; George G Chen; Zhi-Min Liu
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

3.  Epidermal growth factor, its receptor and transforming growth factor-β1 in the diagnosis of HCV-induced hepatocellular carcinoma.

Authors:  Fatma Shehata; Nihad Abdel Monem; Mohamed Sakr; Samar Kasem; Mahmoud Balbaa
Journal:  Med Oncol       Date:  2013-08-03       Impact factor: 3.064

4.  Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors--a novel antiproliferative/antiangiogenic strategy in thyroid cancer.

Authors:  S Hoffmann; S Gläser; A Wunderlich; S Lingelbach; C Dietrich; A Burchert; H Müller; M Rothmund; A Zielke
Journal:  Langenbecks Arch Surg       Date:  2006-10-12       Impact factor: 3.445

5.  VEGF-C Is a Thyroid Marker of Malignancy Superior to VEGF-A in the Differential Diagnostics of Thyroid Lesions.

Authors:  Kosma Woliński; Adam Stangierski; Ewelina Szczepanek-Parulska; Edyta Gurgul; Bartłomiej Budny; Elzbieta Wrotkowska; Maciej Biczysko; Marek Ruchala
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

Review 6.  Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: An update for clinicians (Review).

Authors:  Patrick Reichl; Wolfgang Mikulits
Journal:  Oncol Rep       Date:  2016-06-01       Impact factor: 3.906

7.  Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma.

Authors:  Y Lemos-González; F J Rodríguez-Berrocal; O J Cordero; C Gómez; M Páez de la Cadena
Journal:  Br J Cancer       Date:  2007-04-24       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.